High susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical isolates from Thailand (2018) and South Africa (2015-2017).

We evaluated the susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among recent consecutive clinical isolates cultured in Thailand (n=99; 2018) and South Africa (n=100; 2015-2017). Zoliflodacin was highly active against all tested isolates (MIC range: 0.004-0.25; MIC: 0.064, MIC: 0.125 μg/ml), with no cross-resistance to any of the seven comparator antimicrobials. Our data support the initiation of the global zoliflodacin phase 3 randomized controlled clinical trial for uncomplicated gonorrhea.